Trials / Completed
CompletedNCT05298592
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
A Phase 1 First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Malignant Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986406 administered alone, in combination with nivolumab, or in combination with nivolumab and platinum-doublet chemotherapy (PDCT) in participants with advanced tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMS-986406 | Specified dose on specified days |
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
| DRUG | Carboplatin | Specified dose on specified days |
| DRUG | Pemetrexed | Specified dose on specified days |
| DRUG | Paclitaxel | Specified dose on specified days |
Timeline
- Start date
- 2022-03-31
- Primary completion
- 2024-08-16
- Completion
- 2024-08-16
- First posted
- 2022-03-28
- Last updated
- 2024-09-26
Locations
29 sites across 6 countries: United States, Argentina, Belgium, Japan, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05298592. Inclusion in this directory is not an endorsement.